臺灣博碩士論文加值系統

感染人類微小病毒B19 (B19)已知會促進或誘發許多自體免疫疾病的發生。先前實驗室相關研究已發現B19結構蛋白獨立區域VP1u (B19-VP1u) 與抗磷脂質症候群的自體免疫產生有密切關係。但是B19-VP1u在抗磷脂質症候群的角色仍不清楚。因此，為了釐清B19-VP1u在感染B19病毒及自體免疫疾病中所扮演的角色，我們將抗B19-VP1u抗體作用於人類血管內皮細胞(Human vascular endothelial cells, ECV-304)，探討抗B19-VP1u抗體對人類血管內皮細胞的影響。我們將正常人類IgG抗體、人類抗β2GPI IgG抗體(Human anti-β2GPI IgG)、正常兔子IgG抗體(Rabbit IgG)與兔子抗B19-VP1u抗體(Rabbit anti-human B19-VP1u IgG)分別與人類血管內皮細胞(ECV-304)共同培養，結果發現兔子抗B19-VP1u抗體會促進人類血管內皮細胞黏附因子ICAM-1(CD54)、VCAM-1(CD-106)、E-selectin (CD62E)和MHC-class II (HLA-DR,DP,DQ)的表現及促進發炎細胞激素TNF-α的分泌。因此，由實驗結果可得知抗B19-VP1u抗體具有類似於人類抗β2GPI抗體的功能，可以引起人類血管內皮細胞活化，進而可能誘導抗磷脂症候群疾病的發生。

Human parvovirus B19 infection has been frequently described as a cause or trigger of various autoimmune diseases. In previous studies, we have postulated the association among human parvovirus B19 (B19)-VP1unique region (VP1u), production of anti-beta2-glycoprotein I (anti-β2GPI) antibody and anti-phospholipid syndrome (APS)-like autoimmunity. However, the precise role of B19-VP1u in induction of APS is still obscure. To further elucidate the pathogenic roles of VP1u in B19 infection and autoimmunity, we examined the effect of anti-B19-VP1u IgG antibodies on endothelial cells that is recognized to play crucial roles in APS. Human vascular endothelial cells, ECV-304, were incubated with various preparations of purified human or rabbit IgG. The activation of endothelial cells and production of cytokines were assessed by flow cytometry and ELISA, respectively. Purified IgG from rabbits immunized with recombinant B19-VP1u proteins can up-regulate ICAM-1 (CD54), VCAM-1 (CD106), E-selectin (CD62E), MHC class II (HLA-DR, DP, DQ) molecule expression, and TNF-α production in endothelial cells as compared to those endothelial cells cultured with control IgG. These experimental results imply that antibodies against B19-VP1u play important roles in the immunopathological processes as well as human anti-β2GPI IgG that leads to development of APS. It could provide a clue in understanding the role of anti-B19-VP1u antibodies in APS manifestations.

中文摘要................2

英文摘要.... ..........3

壹、緒論................4

貳、研究動機...........10

參、實驗材料與方法.. .11

肆、結果...............16

伍、討論...............20

陸、參考文獻......... .22

柒、圖表........... ...34

1.Cossart YE, Field AM, Cant B, Widdows D. Parvovirus-like particles in human sera. Lancet.1975; 1 (7898): 72-3.
2.Cossart Y. Parvovirus B19 finds a disease. Lancet. 1981; 2 (8253): 988-9.
3.Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ. The revised criteria for the classification of systemic lupus erythemato-sus. Arthritis Rheum. 1982; 25(11): 1271-77.
4.Pattison JR, Jones SE, Hodgson J, Davis LR, White JM, Stroud CE, Murtaza L. Parvo-virus infections and hypoplastic crisis in sickle-cell anaemia. Lancet. 1981; 1(8221): 664-5.
5.Kerr S, O''Keeffe G, Kilty C, Doyle S. Undenaturated Parvovirus B19 antigens are es-sential for the accurate detection of Parvovirus B19 IgG. J Med Virol.1999; 57(2): 179-85.
6.Sol N, Le Junter J, Vassias I, Freyssinier JM, Thomas A, Prigent AF, Rudkin BB, Fi-chelson S,Morinet F. Possible interactions between the NS-1 protein and tumor necrosis factor alpha pathways in erythroid cell apoptosis induced by human parvovirus B19. J Virol. 1999; 73(10): 8762-70.
7.Biagini P. Human circoviruses. Vet Microbiol. 2004; 98(2): 95-101.
8.Abraham S, Begum S, Isenberg D. Hepatic manifestations of autoimmune rheumatic diseases. Ann Rheum Dis. 2004; 63(2): 123-9.
9.Corcoran A, Doyle S. Advances in the biology, diagnosis and host-pathogen interactions of parvovirus B19. J Med Microbiol. 2004; 53(Pt 6): 459-75.
10. Zhi N, Mills IP, Lu J, Wong S, Filippone C, Brown KE. Molecular and functional ana lyses of a human parvovirus B19 infectious clone demonstrates essential roles for NS1, VP1, and the 11-kilodalton protein in virus replication and infectivity. J Virol. 2006; 80(12): 5941-50.
11.Brown KE, Anderson SM, Young NS. Erythrocyte P antigen: cellular receptor for B19 parvovirus. Science. 1993; 262(5130): 114-7.
12.Cooling LL, Koerner TA, Naides SJ. Multiple glycosphingolipids determine the tissue tropism of Parvovirus B19. J Infect Dis.1995; 172(5): 1198–205.
13.Anderson MJ, Jones SE, Fisher-Hoch SP, Lewis E, Hall SM, Bartlett CL, Cohen BJ, Mortmer PP, Pereira MS. Human parvovirus, the cause of erythema infectiosum (fifth disease)? Lancet 1983; 1(8338): 1378.
14.Anderson MJ, Higgins PG, Davis LR, Willman JS, Jones SE, Kidd IM, Pattison JR, Tyrrell DA. Experimental parvoviral infection in humans. J Infect Dis. 1985; 152(2): 257-65.
15.Serjeant GR, Topley JM, Mason K, Serjeant BE, Pattison JR, Jones SE, Mohamed R. Outbreak of aplastic crisis in sickle cell anaemia associated with parvovirus-like agent. Lancet. 1981; 2(8247): 595-97.
16.White DG, Woolf AD, Mortimer PP, Cohen BJ, Blake DR, Bacon PA. Human parvovi-rus arthropathy. Lancet. 1985; 1(8426): 419-21.
17.Reid DM, Reid TM, Brown T, Rennie JA, Eastmond CJ. Human parvovirus-associated athritis: a clinical and laboratory description. Lancet. 1985; 1(8426): 422-25.
18.Kurtzman GJ, Cohen B, Meyers P, Amunullah A, Young NS. Persistent B19 parvovirus infection as a cause of severe chronic anaemia in children with acute lymphocytic leu-kaemia. Lancet. 1988; 2(8621): 1159-62.
19.Rodis JF, Hovick Jr TJ, Quinn DL, Rosengren SS, Tattersall P. Human parvovirus in-fection in pregnancy. Obstet Gynecol.1988; 72(5): 733-8.
20.Kurtzman G, Frickhofen N, Kimball J, Jenkins DW, Nienhuis AW, Young NS. Pure red-cell aplasia of 10 years’ duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy. N. Engl. J. Med. 1989; 321(8): 519-23.
21.Naides SJ, Scharosch LL, Foto F, Howard EJ. Rheumatologic manifestations of human Parvovirus B19 infection in adults. Initial two-year clinical experience. Arthritis Rheum. 1990; 33(9): 1297-309.
22.Gratacós E, Torres PJ, Vidal J, Antolín E, Costa J, Jiménez de Anta MT, Cararach V, Alonso L, Fortuny A. The incidence of human Parvovirus B19 infection during preg-nancy and its impact on perinatal outcome. J Infect Dis. 1995; 171(5): 1360-3.
23.Yaegashi N, Niinuma T, Chisaka H, Uehara S, Okamura K, Shinkawa O, Tsunoda A, Moffatt S, Sugamura K, Yajima A. Serologic study of human Parvovirus B19 infection in pregnancy in Japan. J Infect. 1999; 38(1): 30-5.
24.Kerr JR. Pathogenesis of human Parvovirus B19 in rheumatic disease. Ann Rheum Dis. 2000; 59(9): 672-83.
25.Blaise G, Nikkels AF, Piérard GE. Cutaneous manifestations of parvovirus B19 infec-tion. Rev Med Liege. 2007; 62(7-8): 492-5.
26.Servey JT, Reamy BV, Hodge J. Clinical presentations of parvovirus B19 infection. Am Fam Physician. 2007; 75(3): 373-6.
27.Zerbini M, Gallinella G, Cricca M, Bonvicini F, Musiani M. Diagnostic procedures in B19 infection. Pathol Biol (Paris). 2002; 50(5): 332-8.
28.Modrow S, Dorsch S. Antibody responses in parvovirus B19 infected patients. Pathol Biol (Paris). 2002; 50(5): 326-31.
29.Manaresi E, Gallinella G, Gentilomi G, Venturoli S, Zuffi E, Bonvicini F, Cricca M, Zerbini M, Musiani M. Humoral immune response to parvovirus B19 and serological diagnosis of B19 infection. Clin Lab. 2002; 48(3-4): 201-5.
30.Patou G, Myint S, Pattison J. Characterization of a nested polymerase chain reaction assay for detection of Parvovirus B19. J Clin Microbiol. 1993; 31(3): 540-6.
31.Bostic JR, Bostic JR, Brown KE, Young NS, Koenig S. Quantitative analysis of neutra-lizing immune responses to human parvovirus B19 using a novel reverse transcrip-tase-polymerase chain reaction-based assay. J Infect Dis. 1999; 179(3): 619-26.
32.von Poblotzki A, Gigler A, Lang B, Wolf H, Modrow S. Antibodies to parvovirus B19 NS-1 protein in infected individuals. J Gen Virol. 1995; 76 ( Pt 3): 519-27.
33.von Poblotzki A, Hemauer A, Gigler A,Puchhammer-Stockl E, Heinz FX, Pont J, Lac-zika K, Wolf H, Modrow S. Antibodies to the nonstructural protein of parvovirus B19 in persistently infected patients: implications for pathogenesis. J Infect Dis. 1995; 172 (5): 1356-9.
34.Katta R. Parvovirus B19 : a review. Dermatol Clin. 2002; 20(2): 333-42.
35.Bultmann BD, Klingel K, Sotlar K, Bock CT, Kandolf R. Parvovirus B19: a pathogen responsible for more than hematologic disorders. Virchows Arch. 2003; 442(1): 8-17.
36.Meyer O. Parvovirus and autoimmune diseases. Joint Bone Spine. 2003; 70(1): 6-11.
37.Young NS, Brown KE. Parvovirus B19. N Engl J Med. 2004; 350(6): 586-97.
38.Raab U, Beckenlehner K, Lowin T, Niller HH, Doyle S, Modrow S. NS1 protein of parvovirus B19 interacts directly with DNA sequences of the p6 promoter and with the cellular transcription factors Sp1/Sp3.Virology. 2002; 293(1): 86-93.
39.Mitchell LA. Parvovirus B19 nonstructural (NS1) protein as a transactivator of inter-leukin-6 synthesis: common pathway in inflammatory sequelae of human parvovirus infections? J Med Virol 2002; 67(2): 267-74.
40.Moffatt S, Tanaka N, Tada K, Nose M, Nakamura M, Muraoka O. A cytotoxic no struc-tural protein, NS1, of human parvovirus B19 induces activation of interleukin-6 gene expression. J Virol 1996; 70(12): 8485-91.
41.Anderson S, Momoeda M, Kawase M, Kajigaya S Young NS. Peptides derived from the unique region of B19 parvovirus minor capsid protein elicit neutralizing antibodies in rabbits. Virology 1995; 206(1): 626–32.
42.Kawase M, Momoeda M, Young NS, Kajigaya S. Most of the VP1 unique region of B19 parvovirus is on the capsid surface. Virology. 1995; 211(2): 359-66.
43.Miyamura K, Kajigaya S, Momoeda M, Smith-Gill SJ, Young NS. Parvovirus particles as platforms for protein presentation. Proc Natl Acad Sci U S A. 1994; 91(18): 8507-11.
44.Musiani M, Manaresi E, Gallinella G, Venturoli S, Zuffi E, Zerbini M. Immunoreactivity against linear epitopes of parvovirus B19 structural proteins. Immunodominance of the amino-terminal half of the unique region of VP1. J Med Virol. 2000; 60(3): 347-52.
45.Wong S, Momoeda M, Field A, Kajigaya S, Young NS. Formation of empty B19 par-vovirus capsids by the truncated minor capsid protein. J Virol. 1994; 68(7): 4690-94.
46.Musiani M, Manaresi E, Gallinelal G. Immunoreactivity against linear epitopes of par-vovirus B19 structural proteins. Immunodominance of the amino-terminal half of the unique region of VP1. J Med Virol. 2000; 60(3): 347-52.
47.Kaufmann B, Simpson AA, Rossmann MG. The structure of human parvovirus B19. Proc Natl Acad Sci U S A. 2004; 101(32): 11628-33.
48.Zadori Z, Szelei J, Lacoste MC. A viral phospholipase A2 is required for parvovirus in-fectivity. Dev Cell. 2001; 1(2): 291–302.
49.Dorsch S, Leibisch G, Kaufmann B. The VP1 unique region of parvovirus B19 and its constituent phospholipase A2-like activity. J Virol. 2002; 76(4): 2014–8.
50.Canaan S, Zadori Z, Ghomashchi F. Interfacial enzymology of parvovirus phospholi-pases A2. J Biol Chem. 2004; 279(15): 14502–8.
51.Lu J, Zhi N, Wong S, Brown KF. Activation of synoviocytes by the secreted phospholi-pase A2 motif in the VP1-unique region of parvovirus B19 minor capsid protein. J In-fect Dis. 2006; 193(4): 582–90.
52.Bönsch C, Kempf C, Ros C. Interaction of parvovirus B19 with human erythrocytes alters virus structure and cell membrane integrity. J Virol. 2008; 82(23): 11784-91.
53.Filippone C, Zhi N, Wong S, Lu J, Kajigaya S, Gallinella G, Kakkola L, Söder-lund-Venermo M, Young NS, Brown KE. VP1u phospholipase activity is critical for in-fectivity of full-length parvovirus B19 genomic clones. Virology. 2008; 374(2): 4444-52.
54.Qu XW, Liu WP, Qi ZY, Duan ZJ, Zheng LS, Kuang ZZ, Zhang WJ, Hou YD. Phos-pholipase A2-like activity of human bocavirus VP1 unique region. Biochem Biophys Res Commun . 2008; 365(1): 158-63.
55.Hsu TC, Tsay GJ. Human parvovirus B19 infection in patients with systemic lupus ery-thematosus. Rheumatology (Oxford) 2001; 40(2): 152–7.
56.Lehmann HW, von Landenberg P, Modrow S. Parvovirus B19 infection and autoim-mune disease. Autoimmun Rev. 2003; 2(4): 218–23.
57.von Landenberg P, Lehmann HW, Modrow S. Human parvovirus B19 infection and an-tiphospholipid antibodies. Autoimmun Rev. 2007; 6(5): 278–85.
58.Lunardi C, Tiso M, Borgato L, Nanni L, Millo R, De Sandre G, Severi AB, Puccetti A. Chronic parvovirus B19 infection induces the production of anti-virus antibodies with autoantigen binding properties. Eur J Immunol. 1998; 28(3): 936-48.
59.Tzang BS, Lee YJ, Yang TP, Tsay GJ, Shi JY, Tsai CC, Hsu TC. Induction of antiphos pholipid antibodies and antiphospholipid syndrome-like autoimmunity in naive mice with antibody against human parvovirus B19 VP1 unique region protein. Clin Chim Acta. 2007; 382(1-2): 31-6.
60.Chou TN, Hsu TC, Chen RM, Lin LI, Tsay GJ. Parvovirus B19 infection associated with the production of anti-neutrophil cytoplasmic antibody (ANCA) and anticardioli-pin antibody (aCL). Lupus. 2000; 9(7): 551-54.
61.Tzang BS, Tsay GJ, Lee YJ, Li C, Sun YS, Hsu TC.The association of VP1 unique re-gion protein in acute parvovirus B19 infection and anti-phospholipid antibody produc-tion. Clin Chim Acta. 2007; 378(1-2):59-65.
62.Asano Y, Sarukawa M, Idezuki T, Harada S, Kaji K, Nakasu I, Igarashi A. Multiple small pulmonary emboli associated with transient antiphospholipid syndrome in human Parvovirus B19 infection. Clin Rheumatol. 2006; 25(4): 585-87.
63.Von Landenberg P, Lehmann HW, Knöll A, Dorsch S, Modrow S. Antiphospholipid antibodies in pediatric and adult patients with rheumatic disease are associated with parvovirus B19 infection. Arthritis Rheum. 2003; 48(7): 1939-47.
64.Loizou S, Cazabon JK, Walport MJ, Tait D, So AK. Similarities of specificity and co-factor dependence in serum antiphospholipid antibodies from patients with human par-vovirus B19 infection and from those with systemic lupus erythematosus. Arthritis Rheum. 1997; 40(1):103-108.
65.Cantalejo Moreira M, Villaverde García V, de las Heras García B, Martín Mola E. Presence of anticardiolipin antibodies in a patient with polyarthritis caused by parvovi-rus B19. Med Clin. 2000; 115(5): 198-99.
66.Avcin T, Toplak N. Antiphospholipid antibodies in response to infection. Curr Rheuma-tol Rep. 2007; 9(3): 212-18.
67.Castanet J, Taillan B, Garnier G, Ragoin O, Ortonne JP, Dujardin P. "Gloves and socks" papular purpura associated with antiphospholipid antibodies. Presse Med. 1993; 22(34): 1747.
68.von Landenberg P, Döring Y, Modrow S, Lackner KJ. Are antiphospholipid antibodies an essential requirement for an effective immune response to infections? Ann N Y Acad Sci. 2007; 1108: 578-83.
69.von Landenberg P, Lehmann HW, Modrow S. Human parvovirus B19 infection and an-tiphospholipid antibodies. Autoimmun Rev. 2007; 6(5): 278-85.
70.Lehmann HW, Plentz A, von Landenberg P, Küster RM, Modrow S. Different patterns of disease manifestations of parvovirus B19-associated reactive juvenile arthritis and the induction of antiphospholipid-antibodies. Clin Rheumatol. 2008; 27(3): 333-38.
71.Lunardi C, Tinazzi E, Bason C, Dolcino M, Corrocher R, Puccetti A. Human parvovirus B19 infection and autoimmunity. Autoimmun Rev. 2008; 8(2): 116-20.
72.Loizou S, Cazabon JK, Walport MJ, Tait D, So AK. Similarities of specificity and co-factor dependence in serum antiphospholipid antibodies from patients with human par-vovirus B19 infection and from those with systemic lupus erythematosus. Arthritis Rheum . 1997; 40(1):103–8.
73.Lehmann HW, Plentz A, Von Landenberg Philipp, Muller-Godeffroy E, Modrow S. In-trave-nous immunoglobulin treatment of four patients with juvenile polyarticular arthri-tis associated with persistent parvovirus B19 infection and antiphospholipid antibodies. Arthritis Res Ther. 2004; 6(1): R1–6.
74.Kalt M, Gertner E. Antibodies to beta 2-glycoprotein I and cardiolipin with symptoms suggestive of systemic lupus erythematosus in parvovirus B19 infection. J Rheumatol. 2001; 28(10): 2335–6.
75.Tzang BS, Tsay GJ, Lee YJ, Li C, Sun YS, Hsu TC. The association of VP1 unique re-gion protein in acute parvovirus B19 infection and antiphospholipid antibody produc-tion. Clinica Chimica Acta. 2007; 378(1-2): 59–65.
76.Lim W, Crowther MA, Eikelboom JW. Management of antiphospholipid antibody syn-drome: a systematic review. JAMA. 2006; 295(9): 1050–7.
77.Field SL, Brighton TA, McNeil HP, Chesterman CN. Recent insights into antiphospho-lipid antibody-mediated thrombosis. Baillieres Best Pract Res Clin Haematol. 1999; 12(3): 407-22.
78.Hanly J. Antiphospholipid syndrome: an overview. CMAJ. 2003; 168(13): 1675-82.
79.Carion R, Zobelem GT, Soria C. Inhibitor of protein C activation by endothelial cells in the presence of lupus anticoagulant (letter). N Engl J Med 1986; 314(18):1193-4.
80.Malia RG, Kitchen S, Greaves M. Inhibition of activated protein C and its cofactor pro-tein S by antiphospholipid antibodies. Br J Haematol 1990; 76(1):101-7.
81.Petri M, Rheinschmidt M, Whiting-O''Keefe P. The frequency of lupus anticoagulant in systemic lupus erythematosus. A study of sixty consecutive patients by activated partial thromboplastin time, Russell viper venom time, and anticardiolipin antibody level. Ann Intern Med 1987; 106(4):524-31.
82.Higasa S, Matsuda T, Ueda M. Activation of normal platelet function by adding anti-phospholipid antibody positive IgG fraction. Thromb Haemost 1993; 69:594a
83.Lindsey NJ, Dawson RA, Henderson FI. Stimulation of von Willebrand factor antigen release by immunoglobulin from thrombosis prone patients with systemic lupus ery-thematosus and the antiphospholipid syndrome. Br J Rheumatol 1993; 32(2):123-6.
84.Rand JH, Wu XX, Andree HA. Pregnancy loss in the antiphospholipid antibody syn-drome—a possible thrombogenic mechanism. N Engl J Med 1997; 337(3):154-60.
85.Hughes G. Thrombosis, abortion, cerebral disease and the lupus anticoagulant. Br Med J. 983; 287(6399): 1088-89.
86.Khamashta M, Cuadrado MJ, Music F. The management of thrombosis in the anti-phospholipid-antibody syndrome. N Engl J Med. 1995; 332(15): 993-97.
87.Miyakis S, Lockshin MD, Atsumi T. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. J Thromb Haemost. 2006; 4(2): 295-306.
88.Wilson WA, Gharavi AE, Koike T. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum. 1999; 42(7): 1309-11.
89.Blank M, Cohen J, Toder V, Shoenfeld Y. Induction of anti-phospholipid syndrome in naïve mice with mouse lupus monoclonal and human polyclonal anticardiolipin antibo-dies. Proc Natl Acad Sci U S A. 1991; 88(8): 3069–73.
90.Pierangeli SS, Harris EN. Clinical laboratory testing for the antiphospholipid syndrome. Clin Chim Acta. 2005; 357(1): 17–33.
91.Bas de laat H, Derksen RH, de Groot PG. beta2-glycoprotein I, the playmaker of the antiphospholipid syndrome. Clin Immunol. 2004; 112(2): 161–8.
92.Ma K, Simantov R, Zhang JC, Silverstein R, Hajjar KA, McCrae KR. High affinity binding of beta 2-glycoprotein I to human endothelial cells is mediated by annexin II. J Biol Chem. 2000; 275(20): 15541–8.
93.Bordron A, Dueymes M, Levy Y, Jamin C, Ziporen L, Piette JC, Shoenfeld Y, Youinou. Anti-endothelial cell antibody binding makes negatively charged phospholipids access-ible to antiphospholipid antibodies. Arthritis Rheum. 1998; 41(10): 1738-47.
94.George J, Afek A, Gilburd B, Blank M, Levy Y, Aron-Maor A, Levkovitz H, Shaish A, Goldberg I, Kopolovic J, Harats D, Shoenfeld Y. Induction of early athero-sclerosis in LDL-receptor-deficient mice immunized with beta2-glycoprotein I. Circulation. 1998; 98(11): 1108-15.
95.Zhang J, McCrae KR. Annexin A2 mediates endothelial cell activation by an-ti-phospholipid/anti-beta2 glycoprotein I antibodies. Blood. 2005; 105(5): 1964-69.
96.D''Ippolito S, Di Simone N, Di Nicuolo F, Castellani R, Caruso A. Antiphospholipid an-tibodies: effects on trophoblast and endothelial cells. Am J Reprod Immunol. 2007; 58(2): 150-58.
97.Meroni PL, Raschi E, Testoni C, Tincani A & Balestrieri G. Antiphospholipid antibodies and the endothelium. Rheum Dis Clin North Am. 2001; 27(3): 587-602.
98.Merrill JT. What causes the antiphospholipid syndrome? Curr Rheumatol Rep. 2001; 3(4): 293-300.
99.Pierangeli SS, Colden-Stanfield M, Liu X, Barker JH, Anderson GL, Harris EN. Anti-phospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo. Circulation. 1999; 99(15): 1997-2002.
100.Pierangeli SS, Espinola RG, Liu X, Harris EN. Thrombogenic effects of anti-phos-pholipid antibodies are mediated by intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and P-selectin. Circ Res. 2001; 88(2): 245-50.
101.Pierangeli SS, Vega-Ostertag M, Harris EN. Intracellular signaling triggered by anti-phospholipid antibodies in platelets and endothelial cells: a pathway to targeted thera-pies. Thromb Res. 2004; 114(5-6): 467-76.
102.Vega-Ostertag M, Liu X, Kwan-Ki H, Chen P, Pierangeli S. A human monoclonal an-tiprothrombin antibody is thrombogenic in vivo and upregulates expression of tissue factor and E-selectin on endothelial cells. Br J Haematol. 2006; 135(2): 214-19.
103.Zhao Y, Rumold R, Zhu M, Zhou D, Ahmed AE, Le DT, Hahn BH, Woods VL Jr, Chen PP. An IgG antiprothrombin antibody enhances prothrombin binding to damaged endothelial cells and shortens plasma coagulation times. Arthritis Rheum. 1999; 42(10): 2132-38.
104.George J, Blank M, Levy Y. Differential effects of anti-beta2-glycoprotein I antibodies on endothelial cells and on the manifestations of experimental antiphospholipid syn-drome. Circulation. 1998; 97(9): 900–6.
105.Cho CS, Cho ML, Chen PP. Antiphospholipid antibodies induce monocyte chemoat-tractant protein-1 in endothelial cells. J Immunol. 2002; 168(8): 4209–15.
106.Turesson C. Endothelial expression of MHC class II molecules in autoimmune disease. Curr Pharm Des. 2004; 10(2): 129–43.
107.Espinola RG, Liu X, Colden-Stanfield M, Hall J, Harris EN, Pierangeli SS. E-Selectin mediates pathogenic effects of antiphospholipid antibodies. J Thromb Haemost. 2003; 1(4): 843-48.
108.Kaplanski G, Cacoub P, Farnarier C, Marin V, Grégoire R, Gatel A, Durand JM, Harlé JR, Bongrand P, Piette JC. Increased soluble vascular cell adhesion molecule-1 concen-trations in patients with primary or systemic lupus erythematosus-related antiphospho-lipid syndrome: correlations with the severity of thrombosis. Arthritis Rheum. 2000; 43(1): 55-64.
109.López-Lira F, Rosales-León L, Martínez VM, Ruiz Ordaz BH. The role of be-ta2-glycoprotein I (beta2GPI) in the activation of plasminogen. Biochim Biophys Acta. 2006; 1764(4): 815-23.
110.Manson JJ, Isenberg DA. Antiphospholipid syndrome. Int J Biochem Cell Biol. 2003; 35(7): 1015-20.
111.Pierangeli SS, Harris EN. Probing antiphospholipid-mediated thrombosis: the interplay between anticardiolipin antibodies and endothelial cells. Lupus. 2003; 12(7): 539-45.
112.Williams FM, Parmar K, Hughes GR, Hunt BJ. Systemic endothelial cell markers in primary antiphospholipid syndrome. Thromb Haemost. 2000; 84(5): 742-46.
113.Camps MT, Cuadrado MJ, Ocón P, Alonso A, Gutierrez A, Guil M, Grana MI, de Ramón E. Association between HLA class II antigens and primary antiphospholipid syndrome from the south of Spain. Lupus. 2003; 4(1): 51-55.
114.Wilson WA. Histocompatibility genes in antiphospholipid antibody syndrome. Lupus. 1996; 5(4): 259-62.
115.Simantov R, Lo SK, Gharavi A, Sammaritano LR, Salmon JE, Silverstein RL. Anti-phospholipid antibodies activate vascular endothelial cells. Lupus. 1996; 5(5): 440–1.
116.Chan E, Winston BW, Uh ST. Evaluation of the role of mitogen-activated protein ki-nases in the expression of inducible nitric oxide synthase by IFN-γ and TNF-α in mouse macrophages. J Immunol. 1999; 162(1): 415–22.
117.Barash J, Dushnitzki D, Barak Y, Miron S, Hahn T.Tumor necrosis factor (TNF) alpha and its soluble receptor (sTNFR) p75 during acute human parvovirus B19 infection in children. Immunol Lett. 2003; 88(2): 109-12.
118.Fu Yi, Ishii Keiko Kumura, Munakata Yasuhiko, Saitoh Takako, Kaku Mitsuo, Sasaki Takeshi. Regulation of tumor necrosis factor alpha promoter by human parvovirus B19 NS1 through activation of AP-1 and AP-2. J Virol. 2002; 76(11): 5395-03.
119.Kerr JR, Barah F, Mattey DL, Laing I, Hopkins SJ, Hutchinson IV & Tyrrell DA. Cir-culating tumour necrosis factor-alpha and interferon-gamma are detectable during acute and convalescent parvovirus B19 infection and are associated with prolonged and chronic fatigue. J Gen Virol. 2001; 82(Pt 12): 3011-19.
120.Kerr JR, McCoy M, Burke B, Mattey DL, Pravica V, Hutchinson IV. Cytokine gene polymorphisms associated with symptomatic parvovirus B19 infection. J Clin Pathol. 2003; 56(10): 725-27.
121.Meroni PL, Borghi MO, Raschi E, Ventura D, Puttini PC, Sarzi, Atzeni F, Lonati L, Parati G, Tincani A, Mari D & Tedesco F. Inflammatory response and the endothelium Thromb Res. 2004; 114(5-6): 329-34.
122.Shi T, Giannakopoulos B, Yan X, Yu P, Berndt MC, Andrews RK, Rivera J, Iverson GM, Cockerill KA, Linnik MD, Krilis SA. Anti-beta2-glycoprotein I antibodies in complex with beta2-glycoprotein I can activate platelets in a dysregulated manner via glycoprotein Ib-IX-V. Arthritis Rheum 2006; 54(8): 2558-67.
123.Jy W, Tiede M, Bidot CJ, Horstman LL, Jimenez JJ, Chirinos J, Ahn YS. Platelet acti-vation rather than endothelial injury identifies risk of thrombosis in subjects positive for antiphospholipid antibodies. Thromb Res. 2007; 121(3): 319-25.
124.Bradley JR. TNF-mediated inflammatory disease. J Pathol. 2008; 214(2): 149-60.